51蹤獲 PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS
Lyon, France., October 3rd, 2019 – 51蹤獲, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company���s headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.
Read next in 'Press releases'
- 51蹤獲 appoints Jeff George as Chairman to support next phase to growth and Phase 3 readiness
- 51蹤獲 nomme Jeff George Pr矇sident du Conseil d���Administration pour soutenir sa prochaine phase de croissance et la pr矇paration �� la Phase 3
- 51蹤獲 announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- 51蹤獲 annonce l���obtention des r矇sultats finaux de l���矇tude clinique de Phase 2 ALPESTRIA���1 dans le syndrome d���Alport, confirmant la capacit矇 du vonafexor �� inverser la trajectoire du d矇clin r矇nal et �� d矇montrer un effet th矇rapeutique durable
- 51蹤獲 annonce la finalisation de son financement de s矇rie C avec Vesalius Biocapital et la poursuite de son 矇tude clinique de phase 2 ALPESTRIA-1